​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​Methodology Detail 

​Symptomatic Treatment Drug Trial Portfolio

1) Data for active Phase 1-3 PD trials was downloaded from ClinicalTrials.gov on April 15, 2021. (n=191 trials)

  •  Active trials have ClinicalTrials.gov "Status" parameter = "Recruiting", "Not yet recruiting", "Active, not recruiting", or "Enrolling by invitation".
  • Of the 191 trials,
    • 152 trials were classified on ClinicalTrials.gov as "Drug" Interventions
    • 39 trials were classified as non-drug Interventions (6 Behavioral, 10 Biological, 3 "Combination Product", 10 Device, 1 Diagnostic Test, 4 Dietary Supplement, 1 Genetic, 2 Other, 2 Procedure).

2) Data for "Recently Completed" Phase 1-3 PD trials was downloaded from ClinicalTrials.gov on April 15, 2021. (n=41 trials)

  • "Recently completed" trials were defined as trials with : "Status" = "Completed", "Terminated", "Withdrawn", or "Status unknown" AND with "Primary completion date" >= January 1, 2020. 

3) 3 studies were excluded

  • NCT04616456: trial of drug Verdiperstat (trial for MSA)
  • NCT04184063: trial of drug NBMI (trial for Atypical only)
  • NCT03944447: cannabis drug trial - questionnaire for 100,000 participants

4) Each trial in 1) and 2) was manually classified as: "Treating symptoms", "Modifying disease progression", "Measuring disease progression", or "Understanding pathology". 

5) 104 trials were identified as evaluations of therapies to treat PD symptoms.  They comprise our Portfolio of Symptomatic Treatment Trials.

  • Includes 91 active trials and 13 recently completed trials. These trials had ClinicalTrials.gov "Intervention" parameter = "Drug", "Biological", "Combination", or "Dietary Supplement").

6) Trials in the Symptomatic Portfolio were also classified as evaluating compounds that are: novel, repurposed (approved to treat another disease or PD symptom) or reformulated.


Data compiled by PD Advocate Sue Buff, with special thanks to PD Advocate Marina Noordegraaf for input on trial classifications.


Trial classification references
ClinicalTrials.gov, scientific journals, industry/academic press releases.
Parkinson’s Disease Drug Therapies in the Clinical Trial Pipeline: 2020, Journal of PD July 2020

​

Note: Symptom descriptors are as provided on ClinicalTrials.gov.

About non-motor symptoms

​​View portfolio (Excel)

PD Symptomatic Treatments in Drug Trials (as of 4/15/21)

Highlights

  • 104 drug trials in ST portfolio, including ​
    • 91 active trials and 13 recently completed trials (since Jan. 2020) 
    • 4 trials for motor/nonmotor symptom, 63 trials for motor symptoms, and 37 trials for non-motor symptoms

​​PDTrialTracker.info


Analyzing the Parkinson's disease clinical trial pipeline to facilitate patient collaboration in research.

About motor symptoms

Q2 2024 dashboards now available!